CARE&GO: Alfasigma's tips for summer!
CARE&GO is Alfasigma's innovative summer social campaign, which will accompany travelers during the summer period, giving advice easy to put into practice everyday....
Read more
Alfasigma launches diagnostic drug Lumeblue™ ahead of World Digestive Health 2022
Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue™ (per-oral methylene blue). This latest innovation is...
Read more
Yovis: Bacterial Fingerprint campaign wins the Consumer Health Category at the Life Science Excellence Awards
Among the top 10 also A_MAB in the HR category. To Alfathon goes the Best PR & Communication project....
Read more
Sulodexide in EVF Guidelines for Prevention of Post-Thrombotic Syndrome (PTS)
New EVF Guidelines publication entitled Management of CVD of lower limbs – Part II reports Sulodexide scientific evidences in the dedicated chapter to Prevention of Post-Thrombotic Syndrome, definin...
Read more
Brilacidin, license agreement with Innovation Pharmaceuticals
Innovation Pharmaceuticals announces License Agreement with Alfasigma S.p.A. for the development and commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis....
Read more
Alfasigma USA Acquires Zelnorm™
Alfasigma USA has acquired the brand ZELNORM (tegaserod), a treatment for IBS-C, from Sloan Pharma, with the aim to relaunch the brand in the United States....
Read more